Liu Xuanjun, Zhao Guowei, Mao Weixu, Li Qigang, Liao Juan, He Gan
Department of Gastrointestinal Surgery, Yongchuan Hospital of Chongqing Medical University, Yongchuan, Chongqing 402160, China.
Department of Respiratory Medicine, The Affiliated Yongchuan District Traditional Chinese Medicine Hospital of Chongqing Medical University, Yongchuan District, Chongqing 402160, China.
Clin Biochem. 2025 Mar;136:110887. doi: 10.1016/j.clinbiochem.2025.110887. Epub 2025 Jan 18.
To investigate the clinical significance of fecal Syndecan-2 (SDC2) gene methylation combined with blood tumor abnormal protein (TAP) detection for the diagnosis of colorectal cancer (CRC) and its precancerous lesions.
A retrospective study was conducted to collect patients diagnosed with CRC or colorectal adenoma (Ade) from March 2020 to March 2023, and healthy people (Nor) without any gastrointestinal diseases during the same period as the control group. All participants underwent the fecal SDC2 gene methylation test, blood TAP test and fecal occult blood test (FOBT). The differences in the positivity rates of each index were compared, receiver operator characteristic curves were plotted and the area under the curve (AUC) was calculated to evaluate the diagnostic effects of different testing methods on CRC and its precancerous lesions.
A total of 146 individuals were included in the study, including 69 CRC patients, 47 patients with Ade and 30 healthy individuals. The results showed that, SDC2, TAP and the combined assay had high comprehensive diagnostic efficacy for the diagnosis of CRC, but there was no significant difference between the three methods in terms of AUC, sensitivity, and specificity. However, for Ade, the combined detection was statistically significant, with a high AUC (0.905), high sensitivity (95.7%), and high specificity (86.7%).
Fecal SDC2 gene methylation combined with blood TAP detection is an effective noninvasive screening and diagnostic method to enhance the early detection and treatment of CRC precancerous lesions, such as Ade, thereby reducing the incidence and mortality of CRC.
探讨粪便Syndecan-2（SDC2）基因甲基化联合血液肿瘤异常蛋白（TAP）检测对结直肠癌（CRC）及其癌前病变诊断的临床意义。
进行一项回顾性研究，收集2020年3月至2023年3月诊断为CRC或结直肠腺瘤（Ade）的患者，以及同期无任何胃肠道疾病的健康人（Nor）作为对照组。所有参与者均接受粪便SDC2基因甲基化检测、血液TAP检测和粪便潜血试验（FOBT）。比较各指标阳性率的差异，绘制受试者工作特征曲线并计算曲线下面积（AUC），以评估不同检测方法对CRC及其癌前病变的诊断效果。
本研究共纳入146例个体，其中CRC患者69例，Ade患者47例，健康个体30例。结果显示，SDC2、TAP及联合检测对CRC诊断具有较高的综合诊断效能，但三种方法在AUC、敏感性和特异性方面无显著差异。然而，对于Ade，联合检测具有统计学意义，AUC较高（0.905），敏感性较高（95.7%），特异性较高（86.7%）。
粪便SDC2基因甲基化联合血液TAP检测是一种有效的非侵入性筛查和诊断方法，可提高对CRC癌前病变（如Ade）的早期发现和治疗，从而降低CRC的发病率和死亡率。
